Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CPT1A | P50416 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | PDE9A | O76083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918615 | 0.84 | PTPN1 (0.36) | PTPN1PDE4BDHFRKDM4CNPC1 | |
| SCHEMBL14488316 | 0.83 | PTPN1 (0.33) | PTPN1PDE4BDHFRKDM4CMEN1 | |
| SCHEMBL16001134 | 0.78 | MMP13 (0.49) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14486051 | 0.77 | KDM6B (0.49) | PTPN1DHFRKDM4CNPC1RAB9A | |
| SCHEMBL14485919 | 0.75 | DAO (0.48) | DHFRKDM4C | |
| SCHEMBL14358192 | 0.75 | TUBB4A (0.38) | PDE4BKDM4CNPC1RAB9ATGFBR1 | |
| SCHEMBL14358188 | 0.75 | TUBB4A (0.38) | PDE4BKDM4CNPC1RAB9ATGFBR1 | |
| SCHEMBL14486125 | 0.75 | DAO (0.50) | DHFRKDM4CNPC1RAB9AMEN1 | |
| SCHEMBL9918614 | 0.75 | PTPN1 (0.35) | PTPN1PDE4BDHFRKDM4CGRM5 | |
| SCHEMBL14554707 | 0.74 | DAO (0.52) | PTPN1KDM4CRAB9APDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100008874-A1 | SUBSTITUTED PYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS EFFECTIVE ABSORBENTS OF UV IRRADIATION | YISSUM RESEARCH DEVELOPMENT COMPANY (IL) | 2010-01-14 | — | — | US | disclosed |
| US-20100008874-A1 | SUBSTITUTED PYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS EFFECTIVE ABSORBENTS OF UV IRRADIATION | YISSUM RESEARCH DEVELOPMENT COMPANY (IL) | 2010-01-14 | — | — | US | disclosed |
| WO-2007116412-A1 | SUBSTITUTED PYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS EFFECTIVE ABSORBENTS OF UV IRRADIATION | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100008874-A1 | SUBSTITUTED PYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS EFFECTIVE ABSORBENTS OF UV IRRADIATION | UNG, UMPS, TYMP | PTPN1 4182/4885PDE4B 2389/4885DHFR 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.